Cardiovascular Diabetology
-
Publication Venue For
-
Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease..
22:72.
2023
-
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes..
22:59.
2023
-
Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease..
21:166.
2022
-
Multi-dimensional characterization of prediabetes in the Project Baseline Health Study..
21:134.
2022
-
Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)..
21:116.
2022
-
Patients phenotypes and cardiovascular risk in type 2 diabetes: the Jackson Heart Study..
21:89.
2022
-
Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis..
21:20.
2022
-
Circulating long chain acylcarnitines and outcomes in diabetic heart failure: an HF-ACTION clinical trial substudy..
20:161.
2021
-
Effects of hybrid comprehensive telerehabilitation on cardiopulmonary capacity in heart failure patients depending on diabetes mellitus: subanalysis of the TELEREH-HF randomized clinical trial..
20:106.
2021
-
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial..
18:138.
2019
-
Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS..
18:116.
2019
-
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk..
17:39.
2018
-
MuRF2 regulates PPARγ1 activity to protect against diabetic cardiomyopathy and enhance weight gain induced by a high fat diet..
14:97.
2015
-
Effects of human immunodeficiency virus and metabolic complications on myocardial nutrient metabolism, blood flow, and oxygen consumption: a cross-sectional analysis.
10:111-111.
2011
-
Cardio-protective effects of carnitine in streptozotocin-induced diabetic rats.
5.
2006
-
Cardio-protective effects of carnitine in streptozotocin-induced diabetic rats..
5:2.
2006